Product logins

Find logins to all Clarivate products below.


Epilepsy is a heterogeneous condition requiring individualized treatment, based largely on a patient’s seizure syndrome and seizure type. Epilepsy patients also differ widely in their responses to treatment with antiepileptic drugs (AEDs) and often are treatment-refractory. As a result, neurologists must consider many factors when selecting among the numerous first-, second-, and third-generation AEDs currently available, and make adjustments—in dosing, or by adding and switching—throughout a patients’ disease course to achieve optimal seizure control. Understanding the many decision points neurologists face in the treatment of epilepsy provides important context about the complex market that developers of investigational AEDs will enter.

How is epilepsy being treated in the United States today, and what are the factors behind those treatment decisions? The Epilepsy Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets. The detailed, expanded analysis in Epilepsy Current Treatment (US) offers a snapshot of how U.S. neurologists are currently managing their epilepsy patients as well as insight into the factors driving such prescribing habits. This new Current Treatment offering provides deep insights, with real-world evidence wherever possible.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Biosimilars – Current Treatment – Endocrinology
Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine to launch in Europe and the United States, followed by Sanofi’s Admelog / Insulin…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…